BioWorld

Aug. 11, 2006

View Archived Issues

ImClone Hurt By Plans To Remain Independent Entity

ImClone Systems Inc. watched its shares drop Thursday following news that the company is nixing its plans for a merger, partnership or outright sale in favor of continuing on alone. (BioWorld Today) Read More

FDA Rejection Of Sparlon Trickles Down To Provigil

Read More

Mouse Model May Help Better Quantify Gene Therapy Risks

Read More

After Phase III Hit With Strep Drug, Advancis Planning NDA

Read More

Neurochem Secures Funding Through $60M Credit Facility

Read More

Other News To Note

Read More

Clinic Roundup

Read More